FPR1 Agonist Program
Pyelonephritis / Complicated UTI (UPEC)
Key Facts
About Inicure
Inicure is a preclinical-stage biotech company pioneering a novel immunomodulatory approach to combat antibiotic-resistant infections. Its core technology involves small molecule FPR1 agonists that activate the NOX2 pathway in neutrophils, boosting the production of reactive oxygen species (ROS) to enhance bacterial killing and resolve inflammation. The company is targeting significant unmet needs in pyelonephritis, chronic wound infections, and MRSA, with a versatile platform applicable to both topical and systemic therapies. Inicure operates as a private entity, originating as a spin-off from Pronoxis AB, and is actively seeking collaborations to advance its programs.
View full company profileAbout Inicure
Inicure is a preclinical-stage biotech company pioneering a novel immunomodulatory approach to combat antibiotic-resistant infections. Its core technology involves small molecule FPR1 agonists that activate the NOX2 pathway in neutrophils, boosting the production of reactive oxygen species (ROS) to enhance bacterial killing and resolve inflammation. The company is targeting significant unmet needs in pyelonephritis, chronic wound infections, and MRSA, with a versatile platform applicable to both topical and systemic therapies. Inicure operates as a private entity, originating as a spin-off from Pronoxis AB, and is actively seeking collaborations to advance its programs.
View full company profileAbout Inicure
Inicure is a preclinical-stage biotech company pioneering a novel immunomodulatory approach to combat antibiotic-resistant infections. Its core technology involves small molecule FPR1 agonists that activate the NOX2 pathway in neutrophils, boosting the production of reactive oxygen species (ROS) to enhance bacterial killing and resolve inflammation. The company is targeting significant unmet needs in pyelonephritis, chronic wound infections, and MRSA, with a versatile platform applicable to both topical and systemic therapies. Inicure operates as a private entity, originating as a spin-off from Pronoxis AB, and is actively seeking collaborations to advance its programs.
View full company profile